XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q3 2026 | — | -0.69 | — | $659,848 | — | +5.01% | -12.72% | — |
| 2026-02-11 | Q2 2026 | — | -0.51 | — | $820,188 | — | -11.11% | -13.23% | -22.12% |
| 2025-11-06 |
| Q1 2026 |
| — |
| -0.44 |
| — |
| $1.1M |
| — |
| — |
| — |
| — |
| 2025-09-23 | Q4 2025 | — | -0.43 | — | $1.3M | — | — | — | — |
| 2025-02-12 | Q2 2025 | — | -3.64 | — | $1.1M | — | -3.13% | +4.06% | -11.88% |
| 2024-11-14 | Q1 2025 | — | -2.71 | — | $1.3M | — | -15.73% | -8.46% | +2.17% |
| 2024-09-30 | Q4 2024 | — | -3.80 | — | $1.3M | — | -6.33% | -9.28% | +23.59% |
| 2024-05-14 | Q3 2024 | — | -3.60 | — | $1.2M | — | +2.62% | +23.30% | -11.05% |
Showing last 8 quarters.